DooresLab

[DooresLab @DooresLab]

PhD opportunity starting Sept 2023. Supervised by Peter Cherepanov (Crick) and myself (KCL). Study mechanisms of SARS-CoV-2 antibody cross-neutralization using X-ray crystallography and cryo-EM.
https://t.co/YXh16LVwlU

[Medical Research Foundation @MedResFdn]

🎉Celebrations are in full swing for our #COVID19 Emerging Leaders Prize winners!

🏆Dr Katie Doores @DooresLab
🏆Dr Rosalind Eggo @rozeggo
🏆Dr Antonia Ho @DrToniHo
🏆Dr Koen Pouwels @kb_pouwels

Huge thanks to our sponsor @Pfizer_UK and speakers @BPhillipsPfizer & @Daltmann10👏

[Nature Microbiology @NatureMicrobiol]

OUT NOW: Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern #SARSCoV2
By Katie Doores & co @DooresLab

read it here: https://t.co/FlADKBzhsd

https://t.co/DN82y4P6zx

[Oliver Pearce @OliverMPearce]

PhD opportunity starting Sept 2021! Sensitising solid cancers to CAR T-cell therapy using matrix remodelling bacteria. You'll be working between @QMBCI and an exciting new biotech start-up.
https://t.co/7q1s0Nct3U

[DooresLab @DooresLab]

We are hiring! 3-year MRC funded postdoc position in the Doores Lab to study humoral immunity to hantaviruses.
https://t.co/idXAfuJAPL

[McHeyzer-Williams @mmw_lmw]

#SARSCoV2_Spike #B117_variant | Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes | Katie Doores @KingsCollegeLon @ImmunityCP https://t.co/29O0N5ZTrk

[DooresLab @DooresLab]

Looking for a postdoc to join our exciting and fast paced research on antibody responses to SARS-CoV-2. https://t.co/mOY3RuyZTf. #antibody #COVID

[DooresLab @DooresLab]

Looking for an enthusiastic and motivated research assistant/tech to work with me and @michael_malim to study the immune response to SARS-CoV-2. https://t.co/6GhfjNGv9R. #antibodies #COVID

[EAVI2020 @eavi2020]

Dr Katie Doores. “Development of a safe and effective HIV vaccine will have a huge impact on global health.” Dr Doores research encompasses the development of carbohydrate-based vaccines and therapeutics, and neutralising antibody responses against pathogenic viruses.